



## **Boule Diagnostics – Invitation to presentation of the interim report Q3 2022**

Boule Diagnostics AB will publish the interim report for the period January – September 2022 at 07:30 CET, Thursday, November 10th, 2022. Following the publication, Boule will hold a Teams Live Event at 10:00 for media and investors.

CEO Jesper Söderqvist and CFO Annette Colin will present and comment on the interim report. After the presentation there will be time for audience questions. The presentation will be held in English.

The interim report will be accessible at [www.boule.com](http://www.boule.com) when published.

*Please feel free to attend this event!*

**Time: 10.00 CET, Thursday, November 10th, 2022**

**[Please follow this link to attend!](#)**

### **For more information, please contact:**

Jesper Söderqvist, CEO and Group President, Boule Diagnostics AB, phone +46 (0)70-689 05 90  
Annette Colin, CFO, Boule Diagnostics AB, phone +46 (0)70-319 06 76

### **About Boule Diagnostics AB (publ)**

Boule Diagnostics AB is a global diagnostics company that develops, manufactures and markets instruments and consumable products for blood diagnostics. The company serves hospitals, clinics, laboratories and companies within blood diagnostics, in both human and veterinary hematology. The company operates via subsidiaries in Sweden, the USA, Mexico and Russia. The company products are sold globally primarily through distributors, supported by Boule's own local sales and support personnel. The Boule shares are listed on Nasdaq Stockholm since 2011. [www.boule.com](http://www.boule.com)

The information was submitted for publication, through the agency of the contact person set out above, at 15.00 CET on November 7, 2022.